PURPOSE: This prospective study was performed to evaluate the effect of chemotherapy-related neurotoxicity on quality of life (QOL) of patients with lymphoma. METHODS: Thirty-two patients with diffuse large B-cell or follicular lymphoma without prior evidence of neuropathy were enrolled. Patients underwent the evaluations based on neuropathy symptom and disability score, nerve conduction studies, and SF-36 questionnaire for QOL assessment. They received six cycles of chemotherapy every three weeks, and all evaluations were repeated during and after the completion of 6th cycle. RESULTS: Sensory neuropathy-associated symptoms were observed in 27 patients (84.4%), and polyneuropathy was confirmed by nerve conduction study in 14 patients (43.8%). These patients with polyneuropathy showed worse QOL in domains mainly associated with physical health status including "physical function" compared to patients without polyneuropathy. There was a significant association of neuropathy symptom and disability scores with "bodily pain" and "vitality" of QOL domains. The serial evaluations of patients with neuropathy showed a worsening of QOL and neuropathy symptom scores during chemotherapy, then improvement of these values after chemotherapy. Thus, the final nerve conduction study confirmed the decrease in polyneuropathy compared to the 2nd evaluation (P = 0.032). CONCLUSION: Chemotherapy-related polyneuropathy may deteriorate QOL of patients with lymphoma, mainly physical health-associated QOL.
PURPOSE: This prospective study was performed to evaluate the effect of chemotherapy-related neurotoxicity on quality of life (QOL) of patients with lymphoma. METHODS: Thirty-two patients with diffuse large B-cell or follicular lymphoma without prior evidence of neuropathy were enrolled. Patients underwent the evaluations based on neuropathy symptom and disability score, nerve conduction studies, and SF-36 questionnaire for QOL assessment. They received six cycles of chemotherapy every three weeks, and all evaluations were repeated during and after the completion of 6th cycle. RESULTS:Sensory neuropathy-associated symptoms were observed in 27 patients (84.4%), and polyneuropathy was confirmed by nerve conduction study in 14 patients (43.8%). These patients with polyneuropathy showed worse QOL in domains mainly associated with physical health status including "physical function" compared to patients without polyneuropathy. There was a significant association of neuropathy symptom and disability scores with "bodily pain" and "vitality" of QOL domains. The serial evaluations of patients with neuropathy showed a worsening of QOL and neuropathy symptom scores during chemotherapy, then improvement of these values after chemotherapy. Thus, the final nerve conduction study confirmed the decrease in polyneuropathy compared to the 2nd evaluation (P = 0.032). CONCLUSION: Chemotherapy-related polyneuropathy may deteriorate QOL of patients with lymphoma, mainly physical health-associated QOL.
Authors: Bertrand Coiffier; Eric Lepage; Josette Briere; Raoul Herbrecht; Hervé Tilly; Reda Bouabdallah; Pierre Morel; Eric Van Den Neste; Gilles Salles; Philippe Gaulard; Felix Reyes; Pierre Lederlin; Christian Gisselbrecht Journal: N Engl J Med Date: 2002-01-24 Impact factor: 91.245
Authors: Marinus H J van Oers; Richard Klasa; Robert E Marcus; Max Wolf; Eva Kimby; Randy D Gascoyne; Andrew Jack; Mars Van't Veer; Andrej Vranovsky; Harald Holte; Martine van Glabbeke; Ivana Teodorovic; Cynthia Rozewicz; Anton Hagenbeek Journal: Blood Date: 2006-07-27 Impact factor: 22.113
Authors: Richard J Klasa; Ralph M Meyer; Chaim Shustik; Carol A Sawka; Anne Smith; Raymond Guévin; Andrew Maksymiuk; Morel Rubinger; Martin Samosh; Suzanne Laplante; Jean-François Grenier Journal: J Clin Oncol Date: 2002-12-15 Impact factor: 44.544
Authors: Deborah Watkins Bruner; Andrea Barsevick; Chunqiao Tian; Marcus Randall; Robert Mannel; David E Cohn; Joel Sorosky; Nick M Spirtos Journal: Qual Life Res Date: 2006-10-11 Impact factor: 4.147
Authors: Tim A Ahles; Andrew J Saykin; Charlotte T Furstenberg; Bernard Cole; Leila A Mott; Linda Titus-Ernstoff; Karen Skalla; Marie Bakitas; Peter M Silberfarb Journal: J Clin Oncol Date: 2005-07-01 Impact factor: 44.544
Authors: Floortje Mols; Tonneke Beijers; Gerard Vreugdenhil; Lonneke van de Poll-Franse Journal: Support Care Cancer Date: 2014-05-01 Impact factor: 3.603
Authors: Kah Poh Loh; Vivian Lam; Katey Webber; Simran Padam; Mina S Sedrak; Vivek Musinipally; Madison Grogan; Carolyn J Presley; Janice Grandi; Chandrika Sanapala; Daniel A Castillo; Grace DiGiovanni; Supriya G Mohile; Louise C Walter; Melisa L Wong Journal: J Natl Compr Canc Netw Date: 2021-04-15 Impact factor: 12.693
Authors: Stefan Hatzl; Florian Posch; Arwin Rezai; Maximilian Gornicec; Christine Beham-Schmid; Theresa Magnes; Sandro Wangner; Alexander Deutsch; Hildegard Greinix; Barbara Uhl; Katharina T Prochazka; Alexander Egle; Richard Greil; Thomas Melchardt; Werner Linkesch; Eduard Schulz; Peter Neumeister Journal: Support Care Cancer Date: 2021-02-24 Impact factor: 3.603
Authors: Tanaya Shree; Qian Li; Sally L Glaser; Ann Brunson; Holden T Maecker; Robert W Haile; Ronald Levy; Theresa H M Keegan Journal: J Clin Oncol Date: 2020-02-21 Impact factor: 50.717